6533b82dfe1ef96bd12908fb

RESEARCH PRODUCT

5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety

Stephan GrabbeMartin KassirTorello LottiRachita DhuratIva BinicHassan GaladariMasa GolubovicAseem SharmaMohamad GoldustMohamad GoldustMohamad GoldustLidia RudnickaGeorge KroumpouzosUwe Wollina

subject

medicine.drug_classDermatologyReductasePharmacology030207 dermatology & venereal diseases03 medical and health sciences5 Alpha-Reductase Inhibitorchemistry.chemical_compound5-alpha Reductase Inhibitors0302 clinical medicinemedicineHumansTestosteronebusiness.industryFinasterideNeurotoxicityAlopeciaAndrogen AntagonistsGeneral MedicineDutasterideDutasteridemedicine.diseaseAndrogenchemistry030220 oncology & carcinogenesisDihydrotestosteroneFinasteridebusinessmedicine.drug

description

Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5-alpha reductase (5-AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5-alpha reductase inhibitor (5-ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

yearjournalcountryeditionlanguage
2020-04-24Dermatologic Therapy
https://doi.org/10.1111/dth.13379